Pierre Fabre launches the pilot for the involvement of blockchain patients


Pierre Fabre Pharmaceuticals has joined a blockchain consortium that allows patients to share digital health data in real time to inform advanced clinical research.

The French pharmaceutical company will work with the Health Blockchain Emblem Consortium on a pilot project to see if the technology can help optimize its patient involvement efforts and provide more effective evidence.

Frédéric Duchesne, CEO of Pierre Fabre, said: "The emergence of digital health is forcing the life sciences industry to abandon the current linear process of drug approval, where regulators make decisions based on paper reports summarizing the data collected years before publication, a new iterative model in which digital health data are shared in real time between patients, life sciences societies and regulatory authorities.

"This means making the most of new technologies, ensuring patient involvement, ensuring data integrity and ensuring the secure transmission of data from patients to life sciences societies and regulators." Blockchain is the key to achieving this vision and we chose Embleema because its technological platform was the most advanced. "

A survey last month found that 60% of pharmaceuticals and life sciences professionals use or experience blockchain today, compared to 22% in 2017.

For his part, Pierre Fabre has helped build the decentralized blockchain network of Embleema, by hosting the nodes to store and share data securely, and dig into the network to ensure the security of sensitive data.

Robert Chu, CEO and founder of Embleema, said: "We are delighted to have Pierre Fabre in our Health Blockchain Consortium and work with them to bring patient involvement and test generation to the next level using Blockchain technology."

Chu, former senior VP of global technology solutions at IMS Health, founded Embleema in June 2017. His blockchain network allows patients to have their health data and consent to share them with drug developers. In doing so, the company states that "it is destroying the slow, costly and opaque process" with which the pharmaceutical industry currently collects health data on the efficacy of new drugs.

[ad_2]Source link